Trial record 1 of 1 for:    risankizumab asthma
Previous Study | Return to List | Next Study

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02443298
Recruitment Status : Completed
First Posted : May 13, 2015
Last Update Posted : September 13, 2018
Boehringer Ingelheim
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2017
  Actual Study Completion Date : February 2018
  Certification/Extension First Submitted : September 12, 2018